RHYTHM PHARMACEUTICALS INC (RYTM)
US76243J1051 - Common Stock
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
December 2025 Options Now Available For Rhythm Pharmaceuticals (RYTM)
The 3 Best Nasdaq Stocks to Buy in May 2024
Although it’s typically the season for selling, shifting market conditions call for the best Nasdaq stocks to buy in May.
RYTM Stock Earnings: Rhythm Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
RYTM stock results show that Rhythm Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
-- First quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to treat...
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
First Week of June 21st Options Trading For Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of...
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on...
Commit To Purchase Rhythm Pharmaceuticals At $25, Earn 8.6% Annualized Using Options
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on...
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
-- Proceeds from financing and existing cash on-hand sufficient to fund planned operations into 2026 --
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
-- Proceeds from financing and existing cash on-hand sufficient to fund planned operations into 2026 --...
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
-- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway --
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on...
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on...
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
-- Supplemental cohort of 12 Japanese patients to be added to global Phase 3 hypothalamic obesity trial, with dosing expected to begin in third quarter of...
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
-- Fourth quarter 2023 net revenue from global sales of IMCIVREE® (setmelanotide) of $24.2 million -- -- Enrollment completed in 120-patient, pivotal...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on...
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Company to participate in fireside chats at Guggenheim’s 6th Annual Biotechnology Conference on Feb. 7 and TD Cowen 44th Annual Health Care Conference on March 5
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Company to participate in fireside chats at Guggenheim’s 6th Annual Biotechnology Conference on Feb. 7 and TD Cowen 44th Annual Health Care Conference on...